Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Abstract Text:

John D Morrey,Venkatraman Siddharthan,Aaron L Olsen,Grant Y Roper,Hong Wang,Thomas J Baldwin,Scott Koenig,Syd Johnson,Jeffrey L Nordstrom,Michael S Diamond,John D Morrey,Venkatraman Siddharthan,Aaron L Olsen,Grant Y Roper,Hong Wang,Thomas J Baldwin,Scott Koenig,Syd Johnson,Jeffrey L Nordstrom,Michael S Diamond,

Humans infected with West Nile virus (WNV) may clinically present with symptoms that are suggestive of neurological infection. Nearly all treatments of WNV disease have been effective in animal models only if administered before or soon after viral challenge. Here, we evaluated whether a potent neutralizing anti-WNV humanized monoclonal antibody (MAb), hE16, could improve the course of disease in a hamster model when administered after the virus had infected neurons in the brain. Five days after viral injection, WNV was detected in the brains of hamsters by cytopathic assay, quantitative reverse-transcription polymerase chain reaction, and immunohistochemical staining of WNV envelope in neurons. Notably, 80%-90% of the hamsters treated 5 days after viral injection by intraperitoneal injection with hE16 survived the disease, compared with 37% of the placebo-treated hamsters (P< or =.001). The hamsters that received hE16 directly in the brain also exhibited markedly improved survival rates, compared with those in the placebo-treated hamsters. In prospective experiments, hamsters with high levels of infectious WNV in their cerebrospinal fluid were also protected by hE16 when administered 5 days after viral injection. These experiments suggest that humanized MAbs with potent neutralizing activity are a possible treatment for human patients after WNV has infected neurons in the central nervous system.

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Publishing Authors By Initials

JD Morrey,V Siddharthan,AL Olsen,GY Roper,H Wang,TJ Baldwin,S Koenig,S Johnson,JL Nordstrom,MS Diamond,JD Morrey,V Siddharthan,AL Olsen,GY Roper,H Wang,TJ Baldwin,S Koenig,S Johnson,JL Nordstrom,MS Diamond,

For similar viruses: rna viruses: flaviviridae: flavivirus: encephalitis viruses, japanese: west nile virus research abstracts see: viruses: rna viruses: flaviviridae: flavivirus: encephalitis viruses, japanese: west nile virus research

PUBMED ID PMID:

MEDLINE DATE:

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Journal Published:

PUBLICATION TYPE: Research Support, N.I.H., Extr

Journal: The Journal of infectious diseases

VOLUME: 194

Page Numbers: 1300-8

Journal Abbreviation: J. Infect. Dis.

ISSN: 0022-1899

DAY: 22

MONTH: 09

YEAR: 2006

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 413675

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Keywords Mesh Terms:

KEYWORDS: West Nile virus

MESH TERMS: immunology

Chemical & Substance for Abstract: Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. Information

Substance Name: palivizumab

Registry Number: 0

Grant and Affiliation Information for Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.

AFFILIATION: Institute for Antiviral Research, Department of Animal, Dairy, and Veterinary Sciences, Utah State University, Logan, UT 84322-4700, USA. jmorrey@cc.usu.edu

Country: United States

AGENCY: United States NIAID

GRANT: U01-AI061373

ACRONYM: AI

MEDLINETA: J Infect Dis

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters Related Publications

• A word to the wise: Tips for the first-time traveler.
• Ambient manganese exposure is negatively associated with human sperm motility and concentration.
• Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein.
• Antibody recognition of cell surface-associated NS1 triggers Fc-gamma receptor-mediated phagocytosis and clearance of West Nile Virus-infected cells.
• Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis.
• Biotinylated photocleavable polyethylenimine: capture and triggered release of nucleic acids from solid supports.
• CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system.
• CD40-CD40 ligand interactions promote trafficking of CD8+ T cells into the brain and protection against West Nile virus encephalitis.
• Caspase 3-dependent cell death of neurons contributes to the pathogenesis of West Nile virus encephalitis.
• Cell-specific IRF-3 responses protect against West Nile virus infection by interferon-dependent and -independent mechanisms.
• Consequences of variations in genes that affect dopamine in prefrontal cortex.
• Defining limits of treatment with humanized neutralizing monoclonal antibody for West Nile virus neurological infection in a hamster model.
• Enhanced discrimination of single nucleotide polymorphism in genotyping by phosphorothioate proofreading allele-specific amplification.
• Functional comparison of T cells recognizing cytomegalovirus pp65 and intermediate-early antigen polypeptides in hematopoietic stem-cell transplant and solid organ transplant recipients.
• Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters.
• In vivo beta-defensin gene expression in rat gingival epithelium in response to Actinobacillus actinomycetemcomitans infection.
• Interrelated and interdependent.
• Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease.
• Matrix protein microarrays for spatially and compositionally controlled microspot thrombosis under laminar flow.
• Methods for mapping protease specificity.
• Microinfusion of pituitary adenylate cyclase-activating polypeptide into the central nucleus of amygdala of the rat produces a shift from an active to passive mode of coping in the shock-probe fear/defensive burying test.
• Novel integrated paired emitter-detector diode (PEDD) as a miniaturized photometric detector in HPLC.
• Selenium and GPx-1 overexpression protect mammalian cells against UV-induced DNA damage.
• Synthesis and structure-activity relationships of a series of increasingly hydrophobic cationic steroid lipofection reagents.
• Systemic lupus erythematosus and Sjögren's syndrome.
• The molecular basis of antibody-mediated neutralization of West Nile virus.
• The relationship of antipsychotic medication class and adherence with treatment outcomes and costs for Florida Medicaid beneficiaries with schizophrenia.
• Thresholds in songbird occurrence in relation to landscape structure.
• Time and recruitment costs as currencies in manipulation studies on the costs of reproduction.
• West Nile virus nonstructural protein NS1 inhibits complement activation by binding the regulatory protein factor H.